Cancer chemotherapy is one of the mainstay treatments for various types of cancers. However, chemotherapy-induced nausea and vomiting (CINV) is a commonly occurring adverse effect of chemotherapy. Anti-emetic drugs play a key role in preventing and managing CINV. They work by blocking receptor signals in the brain that trigger nausea and vomiting. Major classes of anti-emetic drugs include 5-HT3 receptor antagonists, NK1 receptor antagonists, cannabinoids, benzodiazepines, dopamine receptor antagonists, and corticosteroids. The global cancer chemotherapy associated nausea and vomiting therapeutics market offers a variety of prescription drugs belonging to different drug classes that effectively control CINV.

The global cancer chemotherapy associated nausea and vomiting therapeutics market is estimated to be valued at US$ 3537.91 Mn  in 2023 and is expected to exhibit a CAGR of 5.3%  over the forecast period 2024 to 2031, according to a new report by Coherent Market Insights.

Market Dynamics
The cancer chemotherapy associated nausea and vomiting therapeutics market is witnessing high growth owing to the increasing global prevalence of cancer. According to the World Cancer Research Fund International, in 2020, an estimated 19.3 million new cancer cases and 10 million cancer deaths occurred globally. As more cancer cases are diagnosed every year, there will be a corresponding increase in the need for chemotherapy treatments. Since CINV continues to be a common side effect of chemotherapy, the demand for anti-emetic drugs will continue rising steadily over the forecast period. Additionally, the launch of new drug formulations (injectables and oral disintegrating tablets) that are more effective and consumer-friendly is also expected to drive the market growth during the forecast period.

SWOT Analysis
Strength: The cancer chemotherapy associated nausea and vomiting therapeutics market is growing rapidly owing to the rising cases of cancer globally. The increasing government investments in oncology research is expected to drive drug development. Moreover, the availability of various treatment options with patent protection gives competitive advantage to companies.
Weakness: High costs associated with drug development and clinical trials pose significant challenges for small and mid-sized players in this market. Stringent regulatory requirements also result in longer approval timelines. Lack of awareness in developing nations further hinders market growth.
Opportunity: Emergence of novel drug formulations such as sublingual and transdermal options provide growth opportunities. There is scope for development of therapeutics targeting new mechanisms. Growing healthcare expenditure in developing countries will facilitate market expansion in the coming years.
Threats: Patent expiries of major drugs leads to revenue loss for companies. Intense competition from generic formulations also threatens market share of existing players. Possible side effects of chemotherapy drugs may discourage their usage to some extent.

Key Takeaways
The global Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Size  is expected to witness high growth at a CAGR of 5.3%  during the forecast period of 2024 to 2031. The market size is projected to reach US$ 3537.91 Mn  by 2024 from US$ 2375.1 Mn in 2019.

North America currently dominates the global market owing to high cancer incidence and availability of advanced treatments. However, Asia Pacific region is poised to be the fastest growing market for cancer chemotherapy associated nausea and vomiting therapeutics during the forecast period. This can be attributed to rapidly developing pharmaceutical industry, favorable government policies and increasing investments by key players in the region. China and India represent huge growth potentials with presence of leading generic manufacturers. Growing patient access to cancer care owing to rising medical insurance rates will further facilitate market expansion.

Key players operating in the cancer chemotherapy associated nausea and vomiting therapeutics market are Nature Essential Foods Pvt Ltd, Lotus Bakeries, General Mills Inc., Clif Bar & Company, ProBar LLC, Post Holdings Inc., BumbleBar Inc., PepsiCo Inc., Eat Anytime, TORQ Limited, OTE Sports Ltd, Kind LLC, Science in Sports PLC, and Kellogg Company. These companies employ strategies such as new product launches, collaborations and acquisitions to gain market share.

Explore more related article on this topic: https://www.pressreleasebulletin.com/the-global-cancer-chemotherapy-associated-nausea-and-vomiting-therapeutics-market/

https://lotstoexpress.com/unveiling-the-symphony-of-hope-illuminating-cancer-biomarkers-for-precision-diagnosis-and-treatment-advancement/